Immunoteraphy in asthma

Thorax

Volumn 52, Issue SUPPL. 3, 1997, Pages

  Douglass, Jo A ^a   Thien, Francis C K ^a   O'Hehir, Robyn E ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; METHACHOLINE; PLACEBO; RAGWEED ANTIGEN; ALLERGEN;

ADULT; ANAPHYLAXIS; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DANDER; DRUG COST; FORCED EXPIRATORY VOLUME; HAY FEVER; HUMAN; IMMUNOTHERAPY; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MOULD; PEAK EXPIRATORY FLOW; POLLEN ALLERGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SKIN TEST; ANIMAL; DESENSITIZATION; IMMUNOLOGY; METHODOLOGY; MITE; POLLEN; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ALLERGENS; ANIMALS; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; HUMANS; MITES; POLLEN; RANDOMIZED CONTROLLED TRIALS;

EID: 0031205742     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.52.2008.s22     Document Type: Article

References (61)

1. Creticos PS, Reed CE, Norman PS, Khoury J, Adkinson NF, Buncher CR, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996;334:501-6.
2. Creticos PS, Marsh DG, Proud D, Kagney-Subotka A, Adkinson NF, Friedhoff L, et al. Response to ragweed-pollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol 1989;84:197-205.
3. Creticos PS, Norman PS. Letter. N Engl J Med 1996;335:205.
4. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;i:1572.
5. Freeman J. Vaccination against hay fever: report of results during the first three years. Lancet 1914;i:1178.
6. Frew AJ. Injection immunotherapy. BMJ 1993;307:919-23.
7. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265-9.
8. Malling H, Weeke B. Immunotherapy. Position Paper of the European Academy of Allergy and Clinical Immunology. Allergy 1993;48(Suppl 14):9-35.
9. Weiner JM, Walls RS. Specific allergen immunotherapy for asthma. Position paper of the Thoracic Society of Australia and New Zealand.
10. Sporik R, Holgate ST, Platts-Mills TAE, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. N Engl J Med 1990;323:502-7.
11. Peat JK, Britton WJ, Salome CM, Woolcock AJ. Bronchial hyper-responsiveness in two populations of Australian schoolchildren. III. Effect of exposure to environmental allergens. Clin Allergy 1987;17: 283-90.
12. Call RS, Smith TF, Morris E, Chapman M, Platts-Mills TAE. Risk factors for asthma in inner city children. J Pediatr 1992;121:862-6.
13. Peat JK, Tovey E, Mellis CM, Leeder SR, Woolcock AJ. Importance of house dust mite and Alternaria allergens in childhood sthma: an epidemiological study in two climacic regions of Australia. Clin Exp Allergy 1993;23:812-9.
14. Call RS, Ward G, Jackson S, Platts-Mills TAE. Investigating severe and fatal asthma. J Allergy Clin Immunol 1994;94:1065-72.
15. O'Hollaren MT, Yunginger JW, Offord KP, Somers MJ, O'Connell EJ, Ballard DJ. et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med 1991;324:359-63.
16. Chmelik E, Doughty A. Letter. N Engl J Med 1996;335:205.
17. Cockcroft EW, Ruflin RE, Frith PA, Cartier A, Juniper EF, Dolovich J, et al. Determinants of allergen-induced asthma: dose of allergen, circulating IgE antibody concentrations and bronchial responsiveness to inhaled histamine. Am Rev Respir Dis 1982;120:1053-8.
18. Josephs LK, Gregg I, Mullee MA, Holgate ST. Nonspecific bronchial reactivity and its relationship to the clinical expression of asthma. Am Rev Respir Dis 1989;140:350-7.
19. Mailing H-J. Immunotherapy in Europe. Clin Exp Allergy 1994;24: 515-21.
20. Brown JE, Greenberger PA. Immunotherapy and asthma, Immunol Allergy Clin North Am 1993;13:939-61.
21. Adkinson NF, Eggleston PA, Eney D, Goldstein EO, Schuberth KC, Bacon JR, et al. A controlled trial of immunntherapy for asthma in allergic children. N Engl J Med 1997;336:324-31.
22. Barnes PJ. Is immunotherapy worthwhile? N Engl J Med 1996;334:531-2.
23. Reid MJ, Moss RB, Hsu Y-P, Kwasnicki M, Commerford TM, Nelson BE. Seasonal asthma in northern California: allergic causes and efficacy of immunntherapy. J Allergy Clin Immunol 1986;78:590-600.
24. Frankland AW, Augustin R. Prophylaxis of summer hay-fever and asthma. Lancet 1954;i:1055-7.
25. Ortolani C, Pastorello E, Moss RB, Hsu Y-P, Restuccia M, Joppolo G, et al. Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol 1984;73:283-90.
26. Bruce A, Norman PS, Rosenthal RR, Lichtenstein LM. The role of ragweed pollen in autumnal asthma. J Allergy Clin Immunol 1977;59: 440-59.
27. Maunsell KM. Mites and house dust allergy in bronchial asthma. Lancet 1968;i:1267.
28. Turner KJ, Stewart GA, Woolcock AJ, Green W, Alpers MP. Relationship between mite densities and the prevalence of asthma: comparative studies in two populations in the Eastern Highlands of Papua New Guinea. Clin Allergy 1988;18:331-40.
29. Research Committee of the British Tuberculosis Association. Treatment of house dust allergy. BMJ 1968;3:774-7.
30. Maunsell K, Wraith DG, Hughes AM. Hyposensitisation in mite asthma. Lancet 1971;i:967-8.
31. Smith AP. Hyposensitization with Dermatophagoides pteronyssinus antigen: trial in asthma induced by house dust. BMJ 1971;4:204-6.
32. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978;ii:912-5.
33. Price JF, Warner JO. Hey EN, Turner MW, Soothill JF. A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects. Clin Allergy 1984;14:209-19.
34. Pauli G, Bessot JC, Bigot H, Delaume G, Hordle DA, Hirth C, et al. Clinical and immunologic evaluation of tyrosine-adsorbed Dermatophagoides pteronyssinus extract: a double blind placebo-controlled trial. J Allergy Clin Immunol 1984;74:524-35.
35. Gaddie J, Skinner C, Palmer KNV. Hyposensitisation with house dust mite vaccine in bronchial asthma. BMJ 1976;2:561-2.
36. Newton DAG, Maberley DJ, Wilson R. House dust mite hyposensitization. Br J Dis Chest 1978;72:21.
37. Mite Allergy Subcommittee of the Research committee of the British Thoracic Association. A trial of house dust mite extract in bronchial asthma. Br J Dis Chest 1979;73:260-70.
38. Bousquet J, Calvayrac P, Guerin B, Hejjaoui A, Dhivert H, Hewitt B, et al. Immunotherapy with a standardised Dermatophagoides pteronyssinus extract. J Allergy Clin Immunol 1985;76:734-44.
39. Bousquet J, Hejjaoui A, Clauzwl A-M, Guerin B, Dhivert H, Skassa-Brociek W, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. J Allergy Clin Immunol 1988;82:971-7.
40. Peroni DG, Piacentini GL, Martinati LC, Warner JO, Boner AL. Double-blind trial of house-dust mite immunotherapy in asthmatic children resident at high altitude. Allergy 1995;50:925-30.
41. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? Am J Respir Crit Care Med 1995;151:969-74.
42. Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children: a 14 year study. Pediatrics 1968;42: 793-802.
43. Call RS, Ward G, Jackson S, Platts-Mills TAE. Investigating severe and fatal asthma. J Allergy Clin Immunol 1994;94:1065-72.
44. Salvaggio JE, Burge HA, Chapman JA. Emerging concepts in mold immunotherapy: what is the role of immunotherapy? J Allergy Clin Immunol 1993;92:217-22.
45. Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardised Alternaria extract. J Allergy Clin Immunol 1990;85:460-72.
46. Dreborg S, Agrell B, Foucard T, Kjellman NIM, Koivikko A, Nilsson S. A double blind multicentre immunotherapy trial in children using a purified and standardised Cladosporium herbarum preparation. Allergy 1986;41:131-40.
47. Alvarez-Cuesta K, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Harranz C. Blanco-Quiros A. Monoclonal antibody-standardised cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994;93:556-66.
48. Bousquet J. Specific immunotherapy in asthma: is it effective? J Allergy Clin Immunol 1994;94:1-11.
49. Valovirta E, Koivikko A, Vanto T, Viander M, Ingemen L. Immunotherapy in allergy to dog: a double blind clinical study. Ann Allergy 1984;53:85-8.
50. Hedlin G, Heilborn H, Lilja G, Norrlind K, Pegelow KO, Schou C, et al. Long-term follow-up of patients treated with a three year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995;96:879-85.
51. Norman PS, Ohman JL, Long AA, Creticos PS, Gefter MA, Shaked Z, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996;154:1623-8.
52. Simons FER, Imada M, Li Y, Watson WTA, HayGlass KT. Fel d I peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996;8:1937-45.
53. Committee on Safety of Medicines. CSM update. Desensitising vaccines. BMJ 1986;293:948.
54. Stewart GE, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992;90:567-78.
55. Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 1990;85:473-9.
56. Gatien JG, Merler E, Colten HR. Allergy to ragweed antigen E: effect of specific immunotherapy on the reactivity of human T lymphocytes in vitro. Clin Immunol Immunopathol 1975;4:32-7.
57. Akoum H, Tsicopoulos, Vorng H. Venom immonotherapy modulates interleukin-4 and interferon γ messenger RNA expression of peripheral T lymphocytes. Immunology 1996;87:593-8.
58. Jutel MP, Pichler WH, Skrbic D, Urwyler A, Dahinbden C, Muller C. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and an increase of IFN-γ secretion in specific allergen stimulated cultures. J Immunol 1995;25:839-47.
59. Secrist H, DeKruyff H, Umetsu D. Interleukin-4 production by CD4 + cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med 1995;181:1081-9.
60. Hsieh CS, Heimberger AB, Gold JS, O'Garra A, Murphy KM. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an ab T-cell receptor transgenic system. Proc Natl Acad Sci USA 1992;89:6065-9.
61. Varney VA, Hamid QA, Gaga M, Jacobsen MR, Durham SR. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late phase cutaneous responses. J Clin Invest 1993;92:664-51.